Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254794 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL5275846 | 0.81 | — | — | |
| SCHEMBL2266977 | 0.68 | NEK2 (0.32) | NEK2HSD17B10 | |
| SCHEMBL15056816 | 0.67 | GRIN1 (0.30) | — | |
| SCHEMBL10511445 | 0.65 | BACE1 (0.42) | OPRM1HSD17B10 | |
| SCHEMBL16302126 | 0.63 | — | — | |
| SCHEMBL16358641 | 0.62 | IDO1 (0.36) | OPRM1NEK2 | |
| SCHEMBL14829982 | 0.61 | NEK2 (0.42) | OPRM1NEK2 | |
| SCHEMBL2209531 | 0.60 | — | — | |
| SCHEMBL2604297 | 0.60 | NEK2 (0.32) | OPRM1NEK2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | claimed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | claimed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | claimed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | claimed |
| CN-111285875-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-0854869-B1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | LILLY CO ELI (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6693109-B2 | SUCH AS ETHYL(3-(4-(AMINOIMINOMETHYL)PHENYL)-1-OXA-2,8-DIAZA-SPIRO(4.5)DEC-2-EN-8 -YL)ACETATE | ELI LILLY AND COMPANY | 2004-02-17 | — | — | US | disclosed |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2003-09-11 | — | — | US | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | OPRM1 1159/4885NEK2 115/4885HSD17B10 2057/4885 |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | OPRM1 4512/4885NEK2 1046/4885HSD17B10 1401/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | OPRM1 1159/4885NEK2 115/4885HSD17B10 2057/4885 |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | WNT1, CTNNB1, WNT3 | OPRM1 3153/4885NEK2 529/4885HSD17B10 3981/4885 |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | OPRM1 4512/4885NEK2 1046/4885HSD17B10 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.